Association of recipient age and causes of heart transplant mortality: Implications for personalization of post-transplant management—An analysis of the International Society for Heart and Lung Transplantation Registry

Journal of Heart and Lung Transplantation

Volumn 36, Issue 4, 2017, Pages 407-417

  Wever Pinzon, Omar ^a   Edwards, Leah B ^b   Taylor, David O ^c   Kfoury, Abdallah G ^a   Drakos, Stavros G ^a   Selzman, Craig H ^a   Fang, James C ^a   Lund, Lars H ^d   Stehlik, Josef ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b International Society for Heart and Lung Transplantation   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

donor age; heart transplantation; immunosuppression; individualized approach; recipient age; survival

Indexed keywords

ANTIMETABOLITE; BILIRUBIN; CALCINEURIN INHIBITOR; CREATININE; INTERLEUKIN 2 RECEPTOR ANTIBODY; PANEL REACTIVE ANTIBODY; RAPAMYCIN; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGE; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CAUSE OF DEATH; CAUSE SPECIFIC MORTALITY; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMBINATION DRUG THERAPY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS; DIABETES MELLITUS; FEMALE; GENDER; GRAFT FAILURE; GRAFT INFECTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART FAILURE; HEART TRANSPLANTATION; HEPATITIS B VIRUS; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; ISCHEMIA; KIDNEY FAILURE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MEDICAL HISTORY; MEDICAL SOCIETY; MIDDLE AGED; MONOTHERAPY; MORTALITY; MORTALITY RISK; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REGISTER; RENAL REPLACEMENT THERAPY; RISK FACTOR; STEROID THERAPY; SURGICAL MORTALITY; SURGICAL RISK; SURVIVAL ANALYSIS; SURVIVAL RATE; VENTILATOR; VENTRICULAR ASSIST DEVICE; ADOLESCENT; COMPLICATION; GRAFT REJECTION; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; FEMALE; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84995575836     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2016.08.008     Document Type: Article

References (31)

1. 1 Lund, L.H., Edwards, L.B., Kucheryavaya, A.Y., et al. The Registry of the International Society for Heart and Lung Transplantation: thirtieth official adult heart transplant report—2013; focus theme: age. J Heart Lung Transplant 32 (2013), 951–964.
2. 2 Stehlik, J., Feldman, D.S., Brown, R.N., et al. Interactions among donor characteristics influence post-transplant survival: a multi-institutional analysis. J Heart Lung Transplant 29 (2010), 291–298.
3. 3 Wever Pinzon, O., Stoddard, G., Drakos, S.G., et al. Impact of donor left ventricular hypertrophy on survival after heart transplant. Am J Transplant 11 (2011), 2755–2761.
4. 4 Eskandary, F.A., Kohl, M., Dunkler, D., et al. Lack of donor and recipient age interaction in cardiac transplantation. J Heart Lung Transplant 33 (2014), 629–635.
5. 5 Khush, K.K., Kubo, J.T., Desai, M., Influence of donor and recipient sex mismatch on heart transplant outcomes: analysis of the International Society for Heart and Lung Transplantation Registry. J Heart Lung Transplant 31 (2012), 459–466.
6. 6 Kirsch, M., Baufreton, C., Naftel, D.C., Benvenuti, C., Loisance, D.Y., Pretransplantation risk factors for death after heart transplantation: the Henri Mondor experience. J Heart Lung Transplant 17 (1998), 268–277.
7. 7 Borkon, A.M., Muehlebach, G.F., Jones, P.G., et al. An analysis of the effect of age on survival after heart transplant. J Heart Lung Transplant 18 (1999), 668–674.
8. 8 Tsai, F.C., Marelli, D., Bresson, J., et al. Recent trends in early outcome of adult patients after heart transplantation: a single-institution review of 251 transplants using standard donor organs. Am J Transplant 2 (2002), 539–545.
9. 9 Cosio Carmena, M.D., Gomez Bueno, M., Almenar, L., et al. Primary graft failure after heart transplantation: characteristics in a contemporary cohort and performance of the RADIAL risk score. J Heart Lung Transplant 32 (2013), 1187–1195.
10. 10 Singh, T.P., Almond, C.S., Semigran, M.J., Piercey, G., Gauvreau, K., Risk prediction for early in-hospital mortality following heart transplantation in the United States. Circ Heart Fail 5 (2012), 259–266.
11. 11 John, R., Lietz, K., Schuster, M., et al. Older recipient age is associated with reduced alloreactivity and graft rejection after cardiac transplantation. J Heart Lung Transplant, 20, 2001, 212.
12. 12 Marelli, D., Kobashigawa, J., Hamilton, M.A., et al. Long-term outcomes of heart transplantation in older recipients. J Heart Lung Transplant 27 (2008), 830–834.
13. 13 Kaczmarek, I., Sadoni, S., Schmoeckel, M., et al. The need for a tailored immunosuppression in older heart transplant recipients. J Heart Lung Transplant 24 (2005), 1965–1968.
14. 14 George, J.F., Pamboukian, S.V., Tallaj, J.A., et al. Balancing rejection and infection with respect to age, race, and gender: clues acquired from 17 years of cardiac transplantation data. J Heart Lung Transplant 29 (2010), 966–972.
15. 15 George, J.F., Taylor, D.O., Blume, E.D., et al. Minimizing infection and rejection death: clues acquired from 19 years of multi-institutional cardiac transplantation data. J Heart Lung Transplant 30 (2011), 151–157.
16. 16 Kaplan, E.L., Meier, P., Nonparametric estimation from incomplete observations. J Am Statist Assn 53 (1958), 457–481.
17. 17 Mantel, N., Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50 (1966), 163–170.
18. 18 Bradley, B.A., Rejection and recipient age. Transpl Immunol 10 (2002), 125–132.
19. 19 Loupy, A., Cazes, A., Guillemain, R., et al. Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy. Am J Transplant 11 (2011), 1478–1487.
20. 20 Raichlin, E., Bae, J.H., Kushwaha, S.S., et al. Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression. J Am Coll Cardiol 53 (2009), 1279–1286.
21. 21 Nagji, A.S., Hranjec, T., Swenson, B.R., et al. Donor age is associated with chronic allograft vasculopathy after adult heart transplantation: implications for donor allocation. Ann Thorac Surg 90 (2010), 168–175.
22. 22 Braga, J.R., Santos, I.S., McDonald, M., Shah, P.S., Ross, H.J., Factors associated with the development of cardiac allograft vasculopathy—a systematic review of observational studies. Clin Transplant 26 (2012), E111–E124.
23. 23 Whitson, B.A., Kilic, A., Lehman, A., et al. Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents. Clin Transplant 29 (2015), 9–17.
24. 24 Emin, A., Rogers, C.A., Thekkudan, J., Bonser, R.S., Banner, N.R., Steering Group, U.K., Cardiothoracic Transplant Audit. Antithymocyte globulin induction therapy for adult heart transplantation: a UK national study. J Heart Lung Transplant 30 (2011), 770–777.
25. 25 Czer, L.S., Phan, A., Ruzza, A., et al. Antithymocyte globulin induction therapy adjusted for immunologic risk after heart transplantation. Transplant Proc 45 (2013), 2393–2398.
26. 26 Mattei, M.F., Redonnet, M., Gandjbakhch, I., et al. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy. J Heart Lung Transplant 26 (2007), 693–699.
27. 27 Teuteberg, J.J., Shullo, M.A., Zomak, R., et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. Am J Transplant 10 (2010), 382–388.
28. 28 Rosenbaum, D.H., Adams, B.C., Mitchell, J.D., et al. Effects of early steroid withdrawal after heart transplantation. Ann Thorac Surg 82 (2006), 637–644 discussion 644.
29. 29 Baran, D.A., Zucker, M.J., Arroyo, L.H., et al. A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial. Circ Heart Fail 4 (2011), 129–137.
30. 30 Eisen, H.J., Kobashigawa, J., Starling, R.C., et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant 13 (2013), 1203–1216.
31. 31 Andreassen, A.K., Andersson, B., Gustafsson, F., et al. Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial. Am J Transplant 14 (2014), 1828–1838.